By performing phenotypic drug discovery screening assay, the authors found a class of 5‐arylinicotinamide compounds that targeted oxysterol binding protein like 7 and induced ABCA1 expression and cholesterol efflux in cultured podocytes, which might be a potential therapeutic treatment for DKD.37 Here, ABCA1 is linked to diabetic kidney disease.